Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-30T16:53:12.961Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotics for irritability in children with Autism Spectrum Disorders

Published online by Cambridge University Press:  01 September 2022

V. Muñoz Martinez ,
L. Beato-Fernández  and
E. Segura-Escobar
V. Muñoz Martinez*
Affiliation:
Hospital General Universitario de Ciudad Real, Adolescents Inpatient Unit., Ciudad Real, Spain Hospital General Universitario de Ciudad Real, Adolescents Inpatient Unit, Ciudad Real, Spain
L. Beato-Fernández
Affiliation:
Hospital General Universitario de Ciudad Real, Chief Of Psychiatry, Ciudad Real, Spain
E. Segura-Escobar
Affiliation:
Hospital General Universitario de Ciudad Real, Adolescents Inpatient Unit., Ciudad Real, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Autism is a neurodevelopmental disorder characterized by qualitative impairments in social interaction, communication, and restricted and repetitive behaviors [1]. Despite of these symptoms, some patients present different manifestations of irritability. These can be expressed in different kinds of disruptive behaviors. Recent studies shown that, at least 20% of children with autism present irritability symptoms, which cause severe social and familiar disturbances [2].

Objectives

The aim of this study was to evaluate short-term efficacy of aripiprazole in children in comparison with other antipsychotic. We include behaviors related to irritability as all kinds of aggressions, tantrums and self-injuries.

Methods

90 patients were recruited. 45 of the patients received aripiprazole and 45 received other antipsychotic. The initial doses of aripiprazole was 2,5 mg/day. Doses were increase related to symptoms. The range of the doses were from 2,5 to 15 mg/day.

Results

From these 45 patients 12 had a relapse (26,6%) during the next two years. From the second group, 20 (44.4%) of the patients had a relapse during the next two years. Five of the aripiprazole group (11,1%) abandon treatment. From the second group twelve patients (26.6%) also abandon treatment. Prolactin rates with aripiprazole were 28.2 ng/ml for males and 14.1 ng/ml for women.

Conclusions

In general, the result of our research indicated that Aripiprazole was effective and generally safe and well tolerated in the treatment of irritability associated with ASD. One of the limitations was that we do not use scales in order to measure the changes.

Disclosure

No significant relationships.

Keywords

IrritabiltyAutism Spectrum Disorderantipsychoticautism
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S419 - S420
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.